Free Trial
NASDAQ:TRIB

Trinity Biotech (TRIB) Stock Price, News & Analysis

Trinity Biotech logo
$0.66 -0.01 (-0.82%)
Closing price 03/28/2025 03:56 PM Eastern
Extended Trading
$0.66 -0.01 (-1.06%)
As of 03/28/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Trinity Biotech Stock (NASDAQ:TRIB)

Key Stats

Today's Range
$0.64
$0.67
50-Day Range
$0.64
$1.36
52-Week Range
$0.63
$3.55
Volume
28,557 shs
Average Volume
917,053 shs
Market Capitalization
$11.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Remove Ads

Trinity Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

TRIB MarketRank™: 

Trinity Biotech scored higher than 30% of companies evaluated by MarketBeat, and ranked 823rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Trinity Biotech.

  • Earnings Growth

    Earnings for Trinity Biotech are expected to grow in the coming year, from ($1.51) to ($0.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Trinity Biotech is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Trinity Biotech is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Trinity Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    1.33% of the float of Trinity Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Trinity Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trinity Biotech has recently decreased by 8.16%, indicating that investor sentiment is improving significantly.
  • Percentage of Shares Shorted

    1.33% of the float of Trinity Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Trinity Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trinity Biotech has recently decreased by 8.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Trinity Biotech has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Trinity Biotech this week, compared to 1 article on an average week.
  • MarketBeat Follows

    5 people have added Trinity Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trinity Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.20% of the stock of Trinity Biotech is held by insiders.

  • Percentage Held by Institutions

    78.97% of the stock of Trinity Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trinity Biotech's insider trading history.
Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Stock News Headlines

Trinity Biotech (TRIB) Projected to Post Earnings on Thursday
Do this Before Elon's Reveal on April 23rd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Trinity Biotech receives non-compliance notice from Nasdaq
See More Headlines

TRIB Stock Analysis - Frequently Asked Questions

Trinity Biotech's stock was trading at $0.8802 at the beginning of the year. Since then, TRIB stock has decreased by 24.8% and is now trading at $0.6620.
View the best growth stocks for 2025 here
.

Trinity Biotech plc (NASDAQ:TRIB) posted its quarterly earnings results on Monday, May, 24th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.15. The firm had revenue of $25.59 million for the quarter.

Shares of Trinity Biotech reverse split before market open on Wednesday, February 21st 2024. The 1-5 reverse split was announced on Wednesday, February 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Top institutional shareholders of Trinity Biotech include Hunter Associates Investment Management LLC, Renaissance Technologies LLC (1.05%) and Concourse Financial Group Securities Inc..

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trinity Biotech investors own include Bristol-Myers Squibb (BMY), Micron Technology (MU), OPKO Health (OPK), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Pfizer (PFE).

Company Calendar

Last Earnings
5/24/2021
Today
3/29/2025
Next Earnings (Estimated)
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRIB
Employees
480
Year Founded
1992

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,020,000.00
Pretax Margin
-34.56%

Debt

Sales & Book Value

Annual Sales
$59.13 million
Price / Cash Flow
N/A
Book Value
($3.14) per share
Price / Book
-0.21

Miscellaneous

Free Float
16,574,000
Market Cap
$11.95 million
Optionable
Optionable
Beta
1.20

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:TRIB) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners